Author: Proactive Investors

Jeremy Sturgess-Smith, Finance Director of Ananda Developments Plc, presented at the Proactive One2One Investor Forum, highlighting the company’s shift towards addressing chronic pain through medical cannabis. Since its IPO in 2018, Ananda has evolved from a broader investment focus to specialise in conditions like endometriosis, chemotherapy-induced pain, and fibromyalgia. Sturgess-Smith emphasised the significant potential, noting the £5 billion annual NHS expenditure on musculoskeletal pain alone. Ananda aims to offer better treatments for chronic pain, a notoriously difficult condition to manage, by leveraging medical cannabis, which has shown promising results without the adverse effects of traditional therapies. In 2018, the UK…

Read More

MIRA Pharmaceuticals CEO Erez Aminov, CEO joined Proactive’s Stephen Gunnion as the company started trading on the Nasdaq under the ticker symbol ‘MIRA’. Aminov said MIRA is making groundbreaking advancements in the cannabis industry with the development of a synthetic marijuana analog that aims to revolutionize medicinal cannabis usage. This new molecular entity, created using patented technology, offers the benefits of THC and CBD without their typical side effects, such as paranoia, anxiety, and impaired cognition. Clinical studies at John Hopkins Medical School revealed that this compound not only alleviates anxiety and chronic pain but also enhances cognition by 100%…

Read More